StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research report on Monday, August 14th.
Alimera Sciences Trading Up 8.6 %
Alimera Sciences (NASDAQ:ALIM – Get Free Report) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.35. The company had revenue of $23.36 million for the quarter, compared to analyst estimates of $24.40 million. On average, equities analysts forecast that Alimera Sciences will post 0.54 EPS for the current fiscal year.
Insider Activity at Alimera Sciences
In other Alimera Sciences news, major shareholder Caligan Partners Lp purchased 579,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were purchased at an average cost of $3.39 per share, with a total value of $1,962,810.00. Following the completion of the transaction, the insider now owns 16,835,154 shares of the company’s stock, valued at $57,071,172.06. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 31.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. Stonepine Capital Management LLC acquired a new position in Alimera Sciences in the 3rd quarter worth about $12,349,000. AIGH Capital Management LLC acquired a new position in Alimera Sciences in the 3rd quarter worth about $7,355,000. Velan Capital Investment Management LP increased its position in Alimera Sciences by 543.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 1,659,654 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 1,401,901 shares during the last quarter. Worth Venture Partners LLC acquired a new position in Alimera Sciences in the 3rd quarter worth about $1,840,000. Finally, Renaissance Technologies LLC increased its position in Alimera Sciences by 27.9% in the 2nd quarter. Renaissance Technologies LLC now owns 129,716 shares of the biopharmaceutical company’s stock worth $379,000 after purchasing an additional 28,322 shares during the last quarter.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Five stocks we like better than Alimera Sciences
- How to Invest in Toy Stocks
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 11/13 – 11/17
- Video Game Stocks: How to Invest in Gaming
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.